American Oriental Bioengineering To Initiate A Phase One Clinical Trial In The United States Of AOBO-001 Oral Capsule

American Oriental Bioengineering, Inc. (NYSE: AOB), a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter (”OTC”) products, announced that the Company is initiating a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence (UI) in the United States.

More: continued here

Filed under: Clinical Trials on March 11th, 2009